ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
35 announcements with these filters
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.
Rossari Biotech is selling its wholly-owned subsidiary, Rossari International Limited Company, to its Singapore subsidiary for approximately ₹24 Crore. This internal restructuring completes by March 2027.
Rossari Biotech allotted equity shares under its Employee Stock Option Plan - 2019. This adjustment increases the company's issued share capital.
Rossari Biotech's board approved unaudited quarterly financial results, granted 4,000 ESOP options, allotted 2,500 equity shares, and restructured overseas subsidiaries via share transfer to Rossari Singapore.
Rossari Biotech will hold a board meeting on July 18, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Rossari Biotech scheduled its 17th AGM for July 20, 2026. Shareholders will consider a Rs. 1,029 Crore material related party transaction with Unitop Chemicals.
Rossari Biotech dispatched letters to non-email shareholders regarding the annual report. The notice also mentions the 17th AGM scheduled for July 20, 2026.
Rossari Biotech Ltd filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG initiatives and operational footprint.
Rossari Biotech scheduled its 17th AGM for July 20, 2026. The meeting will be conducted via video conferencing.
Rossari Biotech Ltd filed its Integrated Annual Report for FY 2025-26. The filing includes statutory reports and financial statements.
Rossari Biotech started commercial production at its Thailand blending facility. The new plant has an installed capacity of 5000 MTPA.
Rossari Biotech informed that sellers of Unitop Chemicals challenged a January 2026 arbitration award. The petition was filed under the Arbitration and Conciliation Act.
Rossari Biotech Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor confirmed compliance with SEBI regulations with no major deviations noted.
Rossari Biotech has re-appointed Ms. Esha Padmanabhan Achan as an Independent Director for a three-year term. Her extensive finance and strategic planning experience strengthens board oversight.
Rossari Biotech re-appointed Ms. Esha Padmanabhan Achan as Independent Director for three years. The Board also approved granting 830,050 stock options under its 2019 ESOP plan.
Rossari Biotech's subsidiary completed the ₹10.50 Crore sale of its Mumbai office premises. The transaction involves non-related parties and was conducted at arm's length.
Rossari Biotech achieved highest-ever Q4 revenue and EBITDA in FY26, driven by 15% volume-led annual revenue growth. Focus is shifting toward high-margin pharma and oil & gas segments.
Rossari Biotech Limited's board has recommended a final dividend of 25% (Rs. 0.50 per equity share) for the financial year 2025-26. The record date and general meeting date for shareholder approval will be announced later.
Rossari Biotech Limited announced that Ms. Aparna Sharma completed her tenure as Non-Executive Independent Director effective April 28, 2026. This is a routine board transition following the completion of an appointed term.
Rossari Biotech Limited announced that Ms. Aparna Sharma (DIN: 07132341) completed her tenure as an Independent Director on April 28, 2026. Consequently, she ceased to be a director and committee member from the end of that day. The board expressed appreciation for her contributions during her association with the company.
Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.
Rossari Biotech announced its FY26 results, reporting 15% revenue growth to ₹2,396.40 Crore. Q4 FY26 revenue reached a record ₹684.9 Crore, up 18% YoY, while annual PAT rose 9% to ₹149.2 Crore. The company also commissioned 15,000 MTPA additional capacity at its Dahej facility and recommended a ₹0.50 per share dividend.
Rossari Biotech Limited's board recommended a final dividend of 25% (₹0.50 per equity share) for the financial year 2025-26. The record date and general meeting date will be announced later. This proposal is subject to shareholder approval.
Rossari Biotech Limited has appointed Mr. Udeypaul Singh Gill as a Non-Executive Independent Director for a 36-month term effective April 28, 2026. Mr. Gill brings over forty years of experience in chemicals, textiles, and sustainability. The appointment follows a board meeting outcome to strengthen the company's strategic leadership.
Rossari Biotech Limited allotted 8,250 equity shares on April 27, 2026, under its Employee Stock Option Plan - 2019. This allotment increased the company's paid-up share capital from ₹11.08 Crore to ₹11.08 Crore (specifically 5,53,91,616 shares).